Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study

Mauro Silingardi1, Fulvia Zappulo2, Ada Dormi3

  • 1Department of Internal Medicine, Ospedale Maggiore "Carlo Alberto Pizzardi", 40133 Bologna, Italy.

Insights

Severe COVID-19 coagulopathy does not meet criteria for thrombotic microangiopathy (TMA) but involves complement activation and von Willebrand factor (vWF) dysregulation. Elevated vWF collagen-binding activity (vWF-CBA) indicates endothelial dysfunction in severe cases.

Area of Science:

  • Hematology
  • Immunology
  • Pathophysiology of Infectious Diseases

Background:

  • Severe COVID-19 is linked to coagulopathy and thrombosis.
  • Mechanisms include platelet activation, complement dysregulation, and altered von Willebrand factor (vWF)/ADAMTS13 axis.
  • These pathways overlap with thrombotic microangiopathies (TMAs).

Purpose of the Study:

  • To determine if COVID-19 coagulopathy meets TMA criteria.
  • To evaluate the roles of complement activation and vWF/ADAMTS13 imbalance in COVID-19 severity.

Main Methods:

  • Prospective observational study of 43 hospitalized COVID-19 patients.
  • Analysis of hematologic, coagulation, inflammatory, and complement parameters.
  • Stratification by disease severity and 30-day follow-up for outcomes.

Main Results:

  • Elevated vWF and factor VIII in all patients; vWF collagen-binding activity (vWF-CBA) correlated with severity.
  • ADAMTS13 activity >60% and no schistocytes ruled out classical TMA.
  • Severe cases showed higher vWF-CBA/ADAMTS13 ratio, increased C5a, decreased C3b/iC3b, and lower C2 levels, indicating complement activation and endothelial dysregulation.

Conclusions:

  • COVID-19 coagulopathy does not meet classical TMA criteria but exhibits complement-mediated endothelial injury and vWF dysregulation.
  • vWF-CBA may serve as a tool for assessing endothelial dysfunction.
  • Complement system activation is central to the prothrombotic state in severe COVID-19.